Jorey Chernett bought $158k of STLN
owner at Oncology Institute, Inc.. 50,000 shares at an average of $3.15, traded Mar 26, 2026, filed Mar 27, 2026.
Score components
- +12Role10% owner
- +11Trade size$158k at market
- -5Relative to holdingsUnder 1% of holdings (0.5%)
- +8Price context35% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying4 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000921895-26-000814, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | POpen-market purchase Common Stock | +50,000 | $3.15 | $158k | 10,451,929 | Mar 27, 2026 |
Related signals
Other insiders at Oncology Institute, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $81k 27,429 shares | +0% | |
| 36Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $389k 125,000 shares | +1% | |
| 24Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $84k 25,000 shares | +0% | |
| 40Moderate | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $1.2M 398,985 shares | +4% | |
| 22Weak | STLNsell Oncology Institute, Inc. | Robert Ross Carter Chief Financial Officer | $879 247 shares | -0% | |
| 22Weak | STLNsell Oncology Institute, Inc. | Brad Hively director | $50k 13,333 shares | -2% | |
| 32Weak | STLNsell Oncology Institute, Inc. | Mark L Pacala director | $200k 50,000 shares | -22% | |
| 50Moderate | STLNsell Oncology Institute, Inc. | M33 Growth I L.P. director, owner | $21M 6,700,000 shares | -48% | |
| 24Weak | STLNsell Oncology Institute, Inc. | Brad Hively director | $82k 20,221 shares | -3% | |
| 48Moderate | Oncology Institute, Inc. | M33 Growth I L.P. director, owner | $2.3M 750,000 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.